ALK inhibitors (Zenobia Therapeutics/St Jude)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameALK inhibitors (Zenobia Therapeutics/St Jude)
Drug Alias Nameanaplastic lymphoma kinase inhibitors (Zenobia Therapeutics)ALK program (Zenobia Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesZenobia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZenobia Therapeutics IncSt. Jude Children'S Research Hospital
Active IndicationsN/A
Inactive IndicationsNeuroblastoma

Other Information

ATC CodeN/A
Related LinksN/A